Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

ABSTRACT: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with refractory advanced solid tumors or hematologic cancers.

DISEASE(S): Lung Cancer,Leukemia,Melanoma,Colorectal Cancer,Urinary Bladder Neoplasms,Bladder Cancer,Head And Neck Neoplasms,Breast Neoplasms,Lung Neoplasms,Breast Cancer,Unspecified Adult Solid Tumor, Protocol Specific,Ovarian Cancer,Prostatic Neoplasms,Gastric Cancer,Prostate Cancer,Melanoma (skin),Head And Neck Cancer,Stomach Neoplasms,Kidney Cancer

PROVIDER: 2003499 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR